GSK has acquired Massachusetts-based IDRx for up to $1.15bn to develop treatments for gastrointestinal cancers, focusing on GIST. IDRx-42 targets KIT gene mutations, aiming to improve standard care. GSK aims to accelerate drug development and redefine treatment.